Related Experiment Video

Updated: Apr 27, 2026

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

29.5K

Pharmacologic therapy for reducing myocardial infarct size in clinical trials: failed and promising approaches

Sudhakar Sattur1, Sorin J Brener2, Gregg W Stone3

  • 1New York Methodist Hospital, New York, NY, USA.

Journal of Cardiovascular Pharmacology and Therapeutics
|July 3, 2014
PubMed

Insights

Early reperfusion therapy reduces infarct size (IS) and improves survival in ST-segment elevation myocardial infarction. This review covers promising drugs and pathways to further reduce IS and enhance patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Research

Background:

  • Acute ST-segment elevation myocardial infarction (STEMI) requires timely reperfusion for optimal patient outcomes.
  • Reperfusion therapies like fibrinolysis and primary percutaneous coronary intervention significantly improve survival by reducing infarct size (IS) and preserving left ventricular ejection fraction.
  • A direct correlation exists between infarct size and clinical outcomes in myocardial infarction patients.

Purpose of the Study:

  • To review promising pharmacological agents for reducing infarct size (IS) in acute myocardial infarction.
  • To discuss the major biological pathways involved in infarct size reduction.
  • To evaluate clinical trial results of various compounds aimed at limiting myocardial damage.

Main Methods:

  • Literature review of pharmacological agents targeting infarct size reduction.
  • Analysis of major biological pathways implicated in myocardial salvage.
  • Evaluation of clinical trial data for efficacy and safety of therapeutic compounds.

Main Results:

  • Several pharmacological agents show promise in reducing infarct size.
  • Understanding key pathways offers targets for novel therapeutic strategies.
  • Clinical trials demonstrate varying degrees of success for different compounds in limiting myocardial damage.

Conclusions:

  • Pharmacological approaches to infarct size reduction are a critical area of research in acute myocardial infarction.
  • Targeting specific pathways may lead to improved clinical outcomes beyond current reperfusion strategies.
  • Further clinical trials are needed to validate the efficacy of novel agents in reducing infarct size and improving long-term survival.

Keywords:
acute myocardial infarctioninfarct size

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Histological Quantification of Chronic Myocardial Infarct in Rats09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.7K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
342
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
621
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
723